Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in early wet AMD
NCT01402544Phase 3Terminated
- Sponsor
- University of California, San Diego
- Start
- Jul 2011
- Primary completion
- Mar 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in exudative macular degeneration, sponsored by University of California, San Diego. Started Jul 2011; status: terminated.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01402544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402544.